HRP20200925T1 - Pripravak za liječenje dijabetesa koji uključuje analog oksintomodulina - Google Patents
Pripravak za liječenje dijabetesa koji uključuje analog oksintomodulina Download PDFInfo
- Publication number
- HRP20200925T1 HRP20200925T1 HRP20200925TT HRP20200925T HRP20200925T1 HR P20200925 T1 HRP20200925 T1 HR P20200925T1 HR P20200925T T HRP20200925T T HR P20200925TT HR P20200925 T HRP20200925 T HR P20200925T HR P20200925 T1 HRP20200925 T1 HR P20200925T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- diabetes
- prevention
- treatment
- amino acid
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims 13
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 title claims 10
- 230000002265 prevention Effects 0.000 claims 10
- 150000001413 amino acids Chemical group 0.000 claims 9
- 229920000642 polymer Polymers 0.000 claims 7
- 125000001151 peptidyl group Chemical group 0.000 claims 6
- 235000001014 amino acid Nutrition 0.000 claims 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (11)
1. Pripravak za uporabu u prevenciji ili liječenju dijabetesa, naznačen time da pripravak sadrži konjugat analoga oksintomodulina kao aktivni sastojak pri čemu taj konjugat analoga oksintomodulia sadrži
analog oksintomodulina koji sadrži aminokiselinski slijed SEQ ID BR: 24, 25, ili 26;
regiju imunoglobulina Fc; i
ne-peptidil polimer, pri čemu taj ne-peptidil polimer povezuje analog oksintomodulina analog s imunoglobulinom Fc regije putem kovalentne veze.
2. Pripravak za uporabu u prevenciji ili liječenju dijabetesa sukladno patentnom zahtjevu 1, pri čemu analog oksintomodulina sadrži aminokiselinski slijed SEQ ID BR: 24.
3. Pripravak za uporabu sukladno patentnom zahtjevu 1, pri čemu aminokiseline na pozicijama 12 i 16 ili 16 i 20 analoga oksintomodulina tvore prsten, pri čemu taj analog oksintomodulina sukladno SEQ ID BR: 26 ima prsten koji sadrži lizin na poziciji 12 aminokiseline i glutaminsku kiselinu na poziciji 16 aminokiseline i pri čemu analog u skladu sa SEK ID BR:25 ima prsten koji sadrži glutaminsku kiselinu na poziciji 16 aminokiseline i lizin na poziciji 20 aminokiseline.
4. Pripravak za uporabu u prevenciji ili liječenju dijabetesa sukladno patentnom zahtjevu 3, pri čemu analog oksintomodulina sadrži sekvencu aminokiseline iz SEK ID BR: 25.
5. Pripravak za uporabu u prevenciji ili liječenju dijabetesa sukladno patentnom zahtjevu 3, pri čemu analog oksintomodulina obuhvata sekvencu aminokiseline iz SEK ID BR: 26.
6. Pripravak za uporabu u prevenciji ili liječenju dijabetesa sukladno bilo kojem od patentnih zahtjeva, pri čemu je nepeptidil polimer polietilen glikol, polipropilen glikol, kopolimer etilen glikola/propilen glikola, poliooksietilisani poliol, polivinil alkohol, polisaharid, polivinil etil etar, PLA (polilaktidna kiselina), PLGA (polilaktid-glikolna kiselina), lipid polimer, hijaluronska kiselina, ili njihova kombinacija.
7. Pripravak za uporabu u prevenciji ili liječenju dijabetesa sukladno patentnom zahtjevu 6, pri čemu je nepeptidil polimer polietilen glikol.
8. Pripravak za uporabu u prevenciji ili liječenju dijabetesa sukladno patentnom zahtjevu 6, pri čemu je polisaharid dekstran, hitin, ili njihova kombinacija.
9. Pripravak za uporabu u prevenciji ili liječenju dijabetesa sukladno bilo kojem od patentnih zahtjeva, pri čemu je jedan kraj ne-peptidil polimera povezan s imunoglobulinom Fc regije i drugi kraj ne-peptidil polimera je povezan na amino skupinu ili tiol skupinu analoga oksintomodulina.
10. Pripravak za uporabu u prevenciji ili liječenju dijabetesa sukladno bilo kojem od patentnih zahtjeva, nadalje sadrži farmaceutsko sredstvo koje pokazuje preventivne i terapijske učinke protiv dijabetesa.
11. Pripravak za uporabu u prevenciji ili liječenju dijabetesa sukladno bilo kojem od patentnih zahtjeva, pri čemu je taj dijabetes od inzulina ovisan dijabetes tipa 1 ili od inzulina neovisan dijabetes tipa 2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120124724A KR101993393B1 (ko) | 2012-11-06 | 2012-11-06 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| PCT/KR2013/009990 WO2014073845A1 (en) | 2012-11-06 | 2013-11-06 | A composition for treating diabetes or diabesity comprising oxyntomodulin analog |
| EP13853226.2A EP2916860B1 (en) | 2012-11-06 | 2013-11-06 | A composition for treating diabetes comprising oxyntomodulin analog |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200925T1 true HRP20200925T1 (hr) | 2020-09-18 |
Family
ID=50684885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200925TT HRP20200925T1 (hr) | 2012-11-06 | 2020-06-09 | Pripravak za liječenje dijabetesa koji uključuje analog oksintomodulina |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20150299282A1 (hr) |
| EP (2) | EP3679944B1 (hr) |
| JP (4) | JP6363613B2 (hr) |
| KR (1) | KR101993393B1 (hr) |
| CN (1) | CN104918632B (hr) |
| AR (2) | AR093386A1 (hr) |
| AU (3) | AU2013342324B2 (hr) |
| BR (3) | BR112015010203B1 (hr) |
| CA (1) | CA2890329C (hr) |
| CL (1) | CL2015001207A1 (hr) |
| DK (1) | DK2916860T3 (hr) |
| EA (2) | EA037956B1 (hr) |
| ES (1) | ES2802099T3 (hr) |
| HK (1) | HK1211856A1 (hr) |
| HR (1) | HRP20200925T1 (hr) |
| HU (1) | HUE049240T2 (hr) |
| IL (2) | IL238631B (hr) |
| LT (1) | LT2916860T (hr) |
| MX (1) | MX360335B (hr) |
| MY (1) | MY173828A (hr) |
| NZ (2) | NZ738835A (hr) |
| PE (1) | PE20151420A1 (hr) |
| PH (2) | PH12015501009A1 (hr) |
| PL (1) | PL2916860T3 (hr) |
| PT (1) | PT2916860T (hr) |
| SG (3) | SG11201503420QA (hr) |
| TW (4) | TWI645856B (hr) |
| UA (1) | UA117570C2 (hr) |
| WO (1) | WO2014073845A1 (hr) |
| ZA (1) | ZA201503999B (hr) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2718318T (lt) | 2011-06-10 | 2018-10-25 | Hanmi Science Co., Ltd. | Nauji oksintomodulino dariniai ir farmacinė kompozicija, apimanti šiuos darinius, nutukimo gydymui |
| HUE042585T2 (hu) | 2011-06-17 | 2019-07-29 | Hanmi Science Co Ltd | Oxintomodulint és immunglobulin-fragmentumot tartalmazó konjugátum és alkalmazása |
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| SG10201602801YA (en) | 2012-11-06 | 2016-05-30 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
| KR101993393B1 (ko) * | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| MA38276B1 (fr) | 2012-12-21 | 2018-03-30 | Sanofi Sa | Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif. |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| MY192248A (en) * | 2014-03-31 | 2022-08-10 | Hanmi Pharm Ind Co Ltd | Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI772252B (zh) | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| SG11201705376SA (en) | 2014-12-30 | 2017-08-30 | Hanmi Pharm Ind Co Ltd | Glucagon derivative having improved stability |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| KR102005456B1 (ko) | 2015-06-30 | 2019-07-30 | 한미약품 주식회사 | 신규 글루카곤 유도체 및 이의 지속형 결합체를 포함하는 조성물 |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| EP3359191A4 (en) * | 2015-10-05 | 2019-05-29 | Merck Sharp & Dohme Corp. | ANTIBODY-PEPTIDE CONJUGATES HAVING AGONIST ACTIVITY AT GLUCAGON AND PEPTIDE-1 RECEPTORS SIMILAR TO GLUCAGON |
| EP3359194A4 (en) | 2015-10-06 | 2019-04-24 | Merck Sharp & Dohme Corp. | ANTIBODY-ACTIVE CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS |
| EP3398961B1 (en) | 2015-12-31 | 2022-06-29 | Hanmi Pharm. Co., Ltd. | Triple activator activating glucagon, glp-1 and gip receptor |
| WO2017132103A2 (en) | 2016-01-29 | 2017-08-03 | Merck Sharp & Dohme Corp. | Phosphonate linkers and their use to facilitate cellular retention of compounds |
| KR101887576B1 (ko) * | 2016-04-15 | 2018-08-13 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
| SG11201811697SA (en) * | 2016-06-29 | 2019-01-30 | Hanmi Pharmaceutical Co Ltd | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
| BR112019005637A2 (pt) | 2016-09-23 | 2019-07-30 | Hanmi Pharm Ind Co Ltd | análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso |
| CN108299554B (zh) * | 2017-01-13 | 2021-05-25 | 博瑞生物医药（苏州）股份有限公司 | 胃泌酸调节素类似物 |
| CN106986924A (zh) * | 2017-03-23 | 2017-07-28 | 中国药科大学 | 胃泌酸调节素（oxm）类似物及其应用 |
| US11752216B2 (en) | 2017-03-23 | 2023-09-12 | Hanmi Pharm. Co., Ltd. | Insulin analog complex with reduced affinity for insulin receptor and use thereof |
| JP2020535199A (ja) * | 2017-09-29 | 2020-12-03 | ハンミ ファーマシューティカル カンパニー リミテッド | 効力が向上した持続性タンパク質結合体 |
| WO2019171352A2 (en) * | 2018-03-08 | 2019-09-12 | Janssen Pharmaceutica Nv | Methods of treating severe non-diabetic obesity |
| WO2020017919A1 (ko) * | 2018-07-19 | 2020-01-23 | 한미정밀화학주식회사 | 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법 |
| EP3823659A4 (en) * | 2018-07-19 | 2022-06-22 | D&D Pharmatech Inc. | PHARMACEUTICAL COMPOSITION WITH A POLYPEPTIDE |
| KR20200135618A (ko) * | 2019-05-23 | 2020-12-03 | ㈜ 디앤디파마텍 | 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물 |
| US11929171B2 (en) | 2018-10-18 | 2024-03-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for evaluation and treatment of glycemic dysregulation and atherosclerotic cardiovascular disease and applications thereof |
| US20200262887A1 (en) | 2018-11-30 | 2020-08-20 | Opko Ireland Global Holdings, Ltd. | Oxyntomodulin peptide analog formulations |
| WO2020128967A2 (en) * | 2018-12-19 | 2020-06-25 | Janssen Pharmaceutica Nv | Methods of treating severe non-diabetic obesity |
| KR20210118857A (ko) * | 2019-02-15 | 2021-10-01 | 한미정밀화학주식회사 | 생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법 |
| KR102094103B1 (ko) * | 2019-05-08 | 2020-03-27 | ㈜ 디앤디파마텍 | 폴리펩티드를 포함하는 당뇨병 예방 또는 치료용 약학 조성물 |
| WO2022104394A1 (en) * | 2020-11-16 | 2022-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for diagnostic assessment and treatment of insulin resistance and hyperglycemia |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| JP3895109B2 (ja) | 1998-03-06 | 2007-03-22 | 中外製薬株式会社 | 蛋白非添加製剤 |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| US7217845B2 (en) | 2002-11-25 | 2007-05-15 | Sun Bio, Inc. | Bifunctional polyethylene glycol derivatives |
| GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2005035761A1 (en) | 2003-10-16 | 2005-04-21 | Compugen Ltd. | Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin |
| US20090238838A1 (en) | 2003-11-13 | 2009-09-24 | Hanmi Pharm. Ind. Co. Ltd. | Insulinotropic peptide conjugate using an immunoglobulin fc |
| JP4870569B2 (ja) * | 2003-11-13 | 2012-02-08 | ハンミ ホールディングス カンパニー リミテッド | 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法 |
| US8263084B2 (en) * | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| KR101135244B1 (ko) | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
| KR20070094909A (ko) | 2004-12-02 | 2007-09-27 | 도만티스 리미티드 | 혈청 알부민 및 ｇｌｐ-1 또는 ｐｙｙ를 표적으로 삼는이중특이성 도메인을 갖는 항체 |
| WO2006086769A2 (en) | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| WO2007022123A2 (en) | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물 |
| DK1891105T3 (da) | 2005-06-13 | 2012-07-16 | Imp Innovations Ltd | Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd |
| GB0511986D0 (en) | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| WO2007100535A2 (en) | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
| EP2474318A1 (en) | 2006-06-07 | 2012-07-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| GB0624868D0 (en) | 2006-12-13 | 2007-01-24 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| KR20090119876A (ko) | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/ｇｌｐ-1 수용체 공동-항진물질 |
| JP2010533197A (ja) | 2007-07-10 | 2010-10-21 | イーライ リリー アンド カンパニー | ＧＬＰ−１−Ｆｃ融合タンパク質配合物 |
| WO2009040034A2 (en) | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| ES2558155T3 (es) | 2007-10-30 | 2016-02-02 | Indiana University Research And Technology Corporation | Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1 |
| JP2011511778A (ja) | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
| CN103641907A (zh) | 2008-06-17 | 2014-03-19 | 印第安纳大学研究及科技有限公司 | 胰高血糖素/glp-1受体共激动剂 |
| CN104447980A (zh) | 2008-06-17 | 2015-03-25 | 印第安纳大学研究及科技有限公司 | 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物 |
| WO2010013012A2 (en) | 2008-08-01 | 2010-02-04 | Lund University Bioscience Ab | Novel polypeptides and uses thereof |
| US8680263B2 (en) | 2008-09-19 | 2014-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| WO2010033220A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Modified therapeutics peptides, methods of their preparation and use |
| CA2747155A1 (en) * | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| EP2376097A4 (en) | 2008-12-19 | 2012-10-03 | Univ Indiana Res & Tech Corp | AMID-BASED PEPTIDE PRODRUGS OF THE GLUCAGON SUPERFAMILY |
| WO2010096052A1 (en) * | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| BRPI1013626B8 (pt) * | 2009-03-20 | 2021-05-25 | Hanmi Holdings Co Ltd | método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico |
| MX347291B (es) | 2009-03-20 | 2017-04-17 | Amgen Inc | Inmunoglobulinas portadoras y usos de las mismas. |
| MX2011013625A (es) | 2009-06-16 | 2012-01-20 | Univ Indiana Res & Tech Corp | Compuestos glucagon activo de receptor de gip. |
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| EP2496249B1 (en) | 2009-11-03 | 2016-03-09 | Amylin Pharmaceuticals, LLC | Glp-1 receptor agonist for use in treating obstructive sleep apnea |
| US20120269830A1 (en) | 2009-12-07 | 2012-10-25 | Lawrence Horowitz | Conjugates with improved pharmacokinetic properties |
| US8703701B2 (en) * | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| AR079345A1 (es) * | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
| AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
| BR112012024379A2 (pt) | 2010-03-26 | 2017-01-10 | Novo Nordisk As | "peptídeos glucagon, seu uso, bem como composição farmacêutica" |
| BR112012028707A2 (pt) | 2010-05-13 | 2019-09-24 | Univ Indiana Res & Tech Corp | composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo. |
| JP2013540102A (ja) * | 2010-06-24 | 2013-10-31 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | アミド結合を介して修飾されたグルカゴンスーパーファミリーのペプチドプロドラッグ |
| KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| CN101974077A (zh) | 2010-09-15 | 2011-02-16 | 南京瑞年天平医药科技有限公司 | 一种新颖的多肽化合物 |
| KR101303388B1 (ko) | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
| KR101767570B1 (ko) * | 2010-10-26 | 2017-08-14 | 한미사이언스 주식회사 | 항 비만 펩타이드의 지속형 결합체 |
| CN102010473A (zh) | 2010-11-10 | 2011-04-13 | 曹鹏 | 重组胃泌酸调节素融合蛋白及其制备和应用 |
| AU2011348202A1 (en) | 2010-12-22 | 2013-07-04 | Marcadia Biotech, Inc. | Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides |
| EP2492749A1 (en) | 2011-02-28 | 2012-08-29 | Rohm and Haas Electronic Materials LLC | Photoresist compositions and methods of forming photolithographic patterns |
| KR101161526B1 (ko) | 2011-05-16 | 2012-07-02 | 숭실대학교산학협력단 | 연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법 |
| LT2718318T (lt) | 2011-06-10 | 2018-10-25 | Hanmi Science Co., Ltd. | Nauji oksintomodulino dariniai ir farmacinė kompozicija, apimanti šiuos darinius, nutukimo gydymui |
| HUE042585T2 (hu) * | 2011-06-17 | 2019-07-29 | Hanmi Science Co Ltd | Oxintomodulint és immunglobulin-fragmentumot tartalmazó konjugátum és alkalmazása |
| AU2012273365A1 (en) | 2011-06-22 | 2014-01-16 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| MY167814A (en) | 2012-04-19 | 2018-09-26 | Opko Biologics Ltd | Long-acting oxyntomodulin variants and methods of producing same |
| CN104583232B (zh) | 2012-06-21 | 2018-04-13 | 印第安纳大学研究及科技有限公司 | 展现gip受体活性的胰高血糖素类似物 |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| SG10201602801YA (en) * | 2012-11-06 | 2016-05-30 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
| JP6137046B2 (ja) | 2014-05-09 | 2017-05-31 | 信越化学工業株式会社 | 単量体、高分子化合物、レジスト材料及びパターン形成方法 |
-
2012
- 2012-11-06 KR KR1020120124724A patent/KR101993393B1/ko active IP Right Grant
-
2013
- 2013-06-11 UA UAA201504676A patent/UA117570C2/uk unknown
- 2013-11-06 JP JP2015540614A patent/JP6363613B2/ja active Active
- 2013-11-06 EA EA201892383A patent/EA037956B1/ru unknown
- 2013-11-06 HU HUE13853226A patent/HUE049240T2/hu unknown
- 2013-11-06 PL PL13853226T patent/PL2916860T3/pl unknown
- 2013-11-06 EA EA201590759A patent/EA031928B1/ru not_active IP Right Cessation
- 2013-11-06 CN CN201380069535.8A patent/CN104918632B/zh active Active
- 2013-11-06 PT PT138532262T patent/PT2916860T/pt unknown
- 2013-11-06 EP EP20151111.0A patent/EP3679944B1/en active Active
- 2013-11-06 LT LTEP13853226.2T patent/LT2916860T/lt unknown
- 2013-11-06 AU AU2013342324A patent/AU2013342324B2/en active Active
- 2013-11-06 TW TW102140248A patent/TWI645856B/zh active
- 2013-11-06 WO PCT/KR2013/009990 patent/WO2014073845A1/en active Application Filing
- 2013-11-06 NZ NZ738835A patent/NZ738835A/en unknown
- 2013-11-06 TW TW109122403A patent/TWI754980B/zh active
- 2013-11-06 SG SG11201503420QA patent/SG11201503420QA/en unknown
- 2013-11-06 EP EP13853226.2A patent/EP2916860B1/en active Active
- 2013-11-06 BR BR112015010203-4A patent/BR112015010203B1/pt active IP Right Grant
- 2013-11-06 CA CA2890329A patent/CA2890329C/en active Active
- 2013-11-06 TW TW107133431A patent/TWI741218B/zh active
- 2013-11-06 BR BR122019024272-0A patent/BR122019024272B1/pt active IP Right Grant
- 2013-11-06 AR ARP130104070A patent/AR093386A1/es not_active Application Discontinuation
- 2013-11-06 TW TW110124452A patent/TWI755341B/zh active
- 2013-11-06 NZ NZ708105A patent/NZ708105A/en unknown
- 2013-11-06 SG SG10201703732VA patent/SG10201703732VA/en unknown
- 2013-11-06 DK DK13853226.2T patent/DK2916860T3/da active
- 2013-11-06 MY MYPI2015001149A patent/MY173828A/en unknown
- 2013-11-06 ES ES13853226T patent/ES2802099T3/es active Active
- 2013-11-06 MX MX2015005699A patent/MX360335B/es active IP Right Grant
- 2013-11-06 SG SG10202110636WA patent/SG10202110636WA/en unknown
- 2013-11-06 BR BR122021003984-4A patent/BR122021003984B1/pt active IP Right Grant
- 2013-11-06 US US14/440,653 patent/US20150299282A1/en not_active Abandoned
- 2013-11-06 PE PE2015000594A patent/PE20151420A1/es not_active Application Discontinuation
-
2015
- 2015-05-04 IL IL238631A patent/IL238631B/en active IP Right Grant
- 2015-05-06 PH PH12015501009A patent/PH12015501009A1/en unknown
- 2015-05-06 CL CL2015001207A patent/CL2015001207A1/es unknown
- 2015-06-04 ZA ZA2015/03999A patent/ZA201503999B/en unknown
- 2015-12-30 HK HK15112811.5A patent/HK1211856A1/xx unknown
-
2018
- 2018-01-08 AU AU2018200138A patent/AU2018200138B2/en active Active
- 2018-04-23 US US15/960,205 patent/US10550168B2/en active Active
- 2018-06-28 JP JP2018123263A patent/JP6666959B2/ja active Active
- 2018-07-03 PH PH12018501424A patent/PH12018501424B1/en unknown
-
2019
- 2019-12-04 AU AU2019275590A patent/AU2019275590B2/en active Active
-
2020
- 2020-02-21 JP JP2020028080A patent/JP7050834B2/ja active Active
- 2020-03-15 IL IL273305A patent/IL273305B/en unknown
- 2020-06-09 HR HRP20200925TT patent/HRP20200925T1/hr unknown
-
2022
- 2022-02-04 JP JP2022016603A patent/JP7341263B2/ja active Active
- 2022-08-23 AR ARP220102265A patent/AR126851A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200925T1 (hr) | Pripravak za liječenje dijabetesa koji uključuje analog oksintomodulina | |
| IL274106B2 (en) | The composition containing an oxyntomodulin derivative for the treatment of hyperlipidemia | |
| JP2015536943A5 (hr) | ||
| Almeida et al. | Pluronic® F-127 and Pluronic Lecithin Organogel (PLO): main features and their applications in topical and transdermal administration of drugs | |
| Illum | Nasal drug delivery—Recent developments and future prospects | |
| Foley et al. | A chitosan thermogel for delivery of ropivacaine in regional musculoskeletal anesthesia | |
| NZ628828A (en) | Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease | |
| van Gent et al. | Current advances in lipid and polymeric antimicrobial peptide delivery systems and coatings for the prevention and treatment of bacterial infections | |
| WO2013036309A3 (en) | Sustained release formulations for delivery of proteins to the eye and methods of preparing same | |
| HRP20161280T1 (hr) | Farmaceutski pripravci | |
| DK1968638T3 (en) | Controlled release gels | |
| JP2014240439A5 (hr) | ||
| AR068816A1 (es) | Composiciones de brimonidina mejorada para el tratamiento del eritema | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| IN2012DN00407A (hr) | ||
| Constantinou et al. | Pre‐clinical and clinical applications of thermoreversible hydrogels in biomedical engineering: a review | |
| BR112013017750A2 (pt) | nanocápsulas com envoltório polimérico | |
| WO2012022478A3 (en) | Filler composition comprising beta-glucans | |
| Ma et al. | Knee osteoarthritis therapy: recent advances in intra-articular drug delivery systems | |
| Domínguez-Delgado et al. | Chitosan and pluronic® F-127: Pharmaceutical applications | |
| JP2013503165A5 (hr) | ||
| WO2010013495A1 (ja) | 高度精製ボツリヌス毒素治療剤を有効成分として含有する薬学的組成物およびその利用 | |
| EA201100809A1 (ru) | НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ, ВЫСОКООЧИЩЕННЫЙ, СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА АЛЬФА С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ | |
| do Céu Teixeira et al. | Delivery of antimicrobials by chitosan-composed therapeutic nanostructures | |
| Berillo et al. | Stimuli-responsive polymers for transdermal, transmucosal and ocular drug delivery |